Company intelligence
Access Infinity
Specialist consultancy and digital solutions business for market access, pricing and reimbursement teams in Pharma
About Access Infinity
Access Infinity exists to help pharma companies confront their challenges head-on. We began as a consulting firm to guide pharma businesses in developing and implementing effective market access and pricing strategies. We’ve since introduced our market-redefining digital tools, Access Hub, Evidence Library and NURO to help market access teams work smarter, faster and more efficiently with valuable insights at their fingertips. Access Hub helps users track Global market access KPIs and launch activities. It provides Senior Management a single source of truth for tracking reimbursement metrics across multiple products, indications, and regions. NURO is a comprehensive data platform that combines HTA insights, clinical evidence, pricing intelligence, among other critical business insights under a single roof. With +450 data points for every single approved product across all major markets, competitive benchmarking has never been easier. Simply apply relevant matching criteria to identify product analogues in seconds. Evidence Library is a cloud-based platform that facilitates medical/HEOR teams to store, analyse, identify & easily manage evidence generation projects and publications of interest. This tailor-made productivity platform enables effective collaboration from a single repository. Our consultants combine reliable, high-quality data with decades of experience to bring you insights. We are trusted partners to many leading Pharma & Biotech companies on a global scale with projects completed in +40 countries. Your journey to faster, more efficient market access decision-making starts with us. Get in touch to book a meeting with a member of our specialist team, who will be happy to discuss your goals and how we can help.
Verified activity
Signals from Access Infinity
3 published signals
Products & Services
Access Infinity integrated its MFN Risk Predictor with IRP and LSO to run IRP cascades to convergence and test portfolio exposure across launch sequence and optimiser scenarios deterministically.
Reported by Access Infinity
Research & Knowledge
Access Infinity published a whitepaper exploring the challenge of GLP-1s moving beyond obesity, value stories, pricing architecture, and indication sequencing.
Reported by Access Infinity
Presence & Recognition
Access Infinity is hosting a full webinar exploring how Access Hub can be scaled across brands, indications, and markets to give leaders a clearer view of portfolio performance.
Reported by Access Infinity